title: [THE STUDY OF RESPONSE TO TYROSINE KINASE INHIBITORS THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA DEPENDING ON SOCAL SCORE].
abstract: The study included 426 patients with CML in chronic phase treated with imatinib. The level of response to therapy was assessed according to the recommendations of the European Leukemia Net. Socal score determined at the beginning of the disease and was calculated by the appropriate formula. Low risk (n = 150) at 12 months TKI therapy the optimal response was achieved in (66.7 ± 3.8) % of patients, suboptimal--in (20.0 ± 3.3) %, treatment failure is indicated at (13.3 ± 2.8) %. In the intermediate risk group patients (n = 160) at 12 months of treatment the optimal response was obtained in (22.5 ± 3.3) % of patients, suboptimal--in (36.9 ± 3.8) %, the ineffectiveness of treatment--in (40.6 ± 3.9) %. In the high risk group at 12 months of therapy the optimal response achieved in (6.9 ± 2.4) % of patients, suboptimal response--in (19.8 ± 3.7) % and treatment failure in (73.3 ± 4.1) %. A statistically significant difference between the level of response and Socal score are determined. These data suggest about a distinct role Socal score in formation of response to TKI therapy.
authors.forename: Perekhrestenko
authors.initials: P
authors.lastname: T
authors.forename: Dyagil
authors.initials: D
authors.lastname: L
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D012307:Risk Factors; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015415:Biomarkers; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases